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It is not known whether hepatitis C virus (HCV) infection
causes monocytes to differentiate into polarized macro-
phages. We showed that HCV-infected hepatoma cells or cell-
free HCV induce monocyte differentiation into M2-polarized
macrophages, which activate hepatic stellate cells and vali-
dated our ﬁndings in monocytes from chronic HCV patients.
BACKGROUND & AIMS: Monocyte and macrophage (MF)
activation contributes to the pathogenesis of chronic hepatitis C
virus (HCV) infection. Disease pathogenesis is regulated by both
liver-resident MFs and monocytes recruited as precursors of
MFs into the damaged liver. Monocytes differentiate into M1
(classic/proinﬂammatory) or M2 (alternative/anti-inﬂamma-
tory) polarized MFs in response to tissue microenvironment.
We hypothesized that HCV-infected hepatoma cells (infected
with Japanese fulminant hepatitis-1 [Huh7.5/JFH-1]) induce
monocyte differentiation into polarized MFs.
METHODS: Healthy human monocytes were co-cultured with
Huh7.5/JFH-1 cells or cell-free virus for 7 days and analyzed
for MF markers and cytokine levels. A similar analysis was
performed on circulating monocytes and liver MFs from
HCV-infected patients and controls.
RESULTS: Huh7.5/JFH-1 cells induced monocytes to differen-
tiate into MFs with increased expression of CD14 and
CD68. HCV-MFs showed M2 surface markers (CD206, CD163,
and Dendritic cell-speciﬁc intercellular adhesion molecule-3-
grabbing non-integrin (DC-SIGN)) and produced both proin-
ﬂammatory and anti-inﬂammatory cytokines. HCV-induced early
interleukin 1b production promoted transforming growth factor
(TGF)b production and MF polarization to an M2 phenotype.
TGF-b secreted by M2-MF led to hepatic stellate cell activation
indicated by increased expression of collagen, tissue inhibitor of
metalloproteinase 1, and a-smooth muscle actin. In vivo, we
observed a signiﬁcant increase in M2 marker (CD206) expres-
sion on circulating monocytes and in the liver of chronic HCV-
infected patients. Furthermore, we observed the presence of a
unique collagen-expressing CD14þCD206þmonocyte population
in HCV patients that correlated with liver ﬁbrosis.
CONCLUSIONS: We show an important role for HCV in induc-
tion of monocyte differentiation into MFs with a mixed M1/M2
cytokine proﬁle and M2 surface phenotype that promote stel-
late cell activation via TGF-b. We also identiﬁed circulating
monocytes expressing M2 marker and collagen in chronic HCVinfection that can be explored as a biomarker. (Cell Mol Gas-
troenterol Hepatol 2016;2:302–316; http://dx.doi.org/10.1016/
j.jcmgh.2015.12.005)
Keywords: Collagen; Fibrocytes; CD206; Biomarkers.
epatitis C virus (HCV) is a prevalent pathogenHworldwide and is a leading cause of morbidity and
mortality. According to recent estimates, more than 185
million people are infected with HCV and more than 350,000
people die annually from HCV-related liver diseases.1,2
Extensive research has led to the development of various
therapeutic drugs for the disease.3 The US Food and Drug
Administration recently approved 3 new drugs: sofosbuvir
(RNA polymerase inhibitor), simeprevir (protease inhibitor),
and sofosbuvir plus ledipasvir (direct-acting antivirals); thus
marking a new era in HCV treatment because these drugs
achieve sustained virologic response rates greater than 95%
in most patients with shorter treatments and minimal
adverse effects.4 HCV establishes chronicity in 50%–80% of
infected individuals, leading to liver inﬂammation and
ﬁbrosis. Clearance, persistence, and immunopathology of
HCV infection depends on the interplay between the innate
and adaptive immune responses in the liver.
Innate immune cells are important for recognizing HCV
and inﬂuence the outcome of the viral infection.5–10 Prolonged
immune cell activation during chronic infections such as HCV
and human immunodeﬁciency virus can drive viral replication
and viral disease progression.11,12 Monocytes are attracted to
the site of infection and are exposed to viral RNA and protein,
which can lead to their activation.9,13–15 Monocytes are
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sites of infection and differentiate into macrophages (MF)
with distinct phenotypes, and also replenish the Kupffer cells
in the liver.14,16–18 MFs may undergo polarization into clas-
sically activated (M1) or alternatively activated (M2) pheno-
types.19,20 During chronic infection, immune activation can
lead to an anti-inﬂammatory response to limit immunopa-
thology,which can be characterizedby the presence ofM2-like
macrophages. M1 MFs express CD86, major histocom-
patibility complex II, CD40, and CD16 molecules on their
surface, whereas the CD206 (mannose receptor), Dendritic
cell-speciﬁc intercellular adhesion molecule-3-grabbing non-
integrin (DC-SIGN), and CD163 (scavenger receptor) charac-
terize the M2 signature.21,22
Chronic HCV infection leads to progressive hepatic
ﬁbrosis, however, there is a lack of consensus on whether
ﬁbrosis is a direct consequence of the virus infection or a
result of chronic hepatic inﬂammation.23 Although proin-
ﬂammatory cytokines including tumor necrosis factor (TNF)
a and interleukin (IL)1b have been implicated in the ﬁbrosis
process, anti-inﬂammatory transforming growth factor
(TGF)-b is the most potent proﬁbrogenic cytokine.24–27 A
study by Li et al28 showed that TGF-b produced by HCV-
speciﬁc intrahepatic lymphocytes (T-regulatory cells)
correlated inversely with liver ﬁbrosis. This implies the
presence of yet another cellular source of TGF-b, which
leads to hepatic stellate cell (HSC) activation and ﬁbrosis in
chronic HCV infection. Because of the lack of small animal
models of HCV infection, in vitro culture systems have been
used to study the activation and function of immune cells.29
In this study, we evaluated changes in the phenotype and
function of healthy human monocytes cultured in the
presence of HCV-infected hepatoma cells or cell-free HCV.
We present evidence that HCV can induce circulating
monocytes to differentiate into macrophages with a mixed
M1/M2 cytokine production and M2 surface marker
expression. We also show that chronic presence of HCV can
program monocytes and induce HSC activation via TGF-b
during HCV infection. Finally, we delineated a unique pop-
ulation of circulating monocytes with both M2 marker and
collagen expression in chronic HCV-infected patients that
correlated with the presence of liver ﬁbrosis.Materials and Methods
Biological Materials and Reagents
Huh7.5 cells were kindly provided by Dr Charles Rice
(Rockefeller University, New York, NY) and were maintained
in low-glucose Dulbecco’s modiﬁed Eagle medium containing
10% fetal bovine serum (Hyclone, Logan, UT), 10 mg/mL
ciproﬂoxacin, and supplemented with nonessential amino
acids (NEAA) (Gibco, Grand Island, NY). The Japanese fulmi-
nant hepatitis-1 (JFH-1) (HCV) construct was provided by Dr
Takaji Wakita (National Institute of Infectious Diseases,
Tokyo, Japan). In vitro synthesized JFH-1 RNA constructs
were transfected and JFH-1 virus stock were produced as
previously described.30 HCV viral supernatants were
collected from Huh7.5 cells highly infected with JFH-1 cell
culture–derived HCV particles and determined by ﬂowcytometry.30 The supernatant was passed through 0.22-mm
ﬁlters and was concentrated 20–30 times using an Amicon
Ultra-15 100K centrifugal ﬁlter unit, and virus stock
was preserved at -80C (Millipore, Billerica, MA).30 Unin-
fected Huh7.5 cell supernatant was collected, concentrated,
and was used as controls. Human liver biopsy specimens
evaluated from 12 patientswith chronic HCV (Supplementary
Table 1) and 11 controls were received as anonymized sam-
ples by the National Institutes of Health–Funded Liver Tissue
Procurement and Cell Distribution System. Human peripheral
blood was collected from healthy donors and HCV-infected
patients (Supplementary Table 2) with approval from the
Institutional Review Board for the Protection of Human
Subjects in Research at the University of Massachusetts
Medical School with written informed consent. All authors
had access to the study and reviewed and approved the ﬁnal
manuscript.
Dulbecco’s modiﬁed Eagle medium and RPMI 1640 cell
culture media, antibiotics, and NEAA were purchased from
Gibco. Recombinant TGF-b was purchased from Peprotech
(Rocky Hill, NJ). Human (latency associated peptide)
TGF-b1 antibody and mouse IgG1 isotype control were
purchased from R&D Systems (Minneapolis, MN). Human
antibodies (CD16 Allophycocyanin [APC], CD14 ﬂuorescein
isothiocyanate [FITC], CD40 FITC, and CD86 Phycoerythrin
[PE]) were purchased from eBioscience (San Diego, CA),
and CD14 APC, CD14 PE, CD163 PE, CD11c APC, CD68 PE,
CD206 APC, DC-SIGN-FITC, CD45 PE, CD14 PE-Cy7,
and isotype control antibodies were purchased from BD
Pharmingen (Franklin Lakes, NJ). a-Smooth muscle actin
(a-SMA) antibody, CD68 antibody, CD206 antibody, and
FITC-conjugated donkey anti-rabbit IgG were purchased
from Abcam (Cambridge, MA).Human Monocyte Isolation and
Co-culture Experiments
Human peripheral blood was collected from healthy
donors, monocytes were isolated to more than 95% purity
from peripheral blood mononuclear cells (PBMCs) by using
CD14 microbeads, an MS Column, and a MiniMACS sepa-
rator (Miltenyi Biotec, Inc, San Diego, CA), and were
conﬁrmed by ﬂow cytometry (Supplementary Figure 1).
Monocytes were cultured in RPMI 1640 medium (Gibco),
supplemented with 10% fetal bovine serum, 100 U/mL
penicillin, 100 mg/mL streptomycin, and NEAA as described
previously.15 Informed consent was obtained and approved
by the Institutional Review Board for the Protection
of Human Subjects in Research at the University of Massa-
chusetts Medical School. Huh7.5 or Huh7.5/JFH-1
cells (48 hours after infection) were plated on 12-well
plates (2.5  105 cells/well) and co-cultured with mono-
cytes (5  105 cells) in a 37C, 5% CO2 incubator for 7 days.
Monocytes were treated with HCV concentrate and Huh7.5
concentrate for 7 days. Supernatants, cells, and RNA were
collected from all these experiments at the indicated time
points and surface markers and cytokine expression were
studied. To study stellate cell activation, the HSC cell line
LX2 (2  105 cells/well) was cultured in the presence of
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co-culture experiments and the proﬁbrogenic gene and
protein expressions were evaluated.
Enzyme-Linked Immunosorbent Assay
Levels of TNFa and IL1b were quantiﬁed in cell culture
supernatant using commercially available enzyme-linked
immunosorbent assay kits from BD Biosciences (Franklin
Lakes, NJ). Enzyme-linked immunosorbent assay kits from
eBioscience were used to measure IL10 and TGF-b in the
cell culture supernatant.
RNA Extraction and Quantiﬁcation
RNA was extracted using the RNeasy Mini kit (Qiagen,
Valencia, CA) and 2-step real-time polymerase chain reac-
tion as described previously30 using primers described in
Supplementary Table 3. The level of the target gene
expression was measured by the DDCt method using the
ratio of the fold-change in target gene expression vs the
fold-change in reference gene expression (glyceraldehyde-
3-phosphate dehydrogenase or 18S ribosomal RNA).
Flow Cytometry
To analyze cell surface marker expression, monocytes
were immunostained for 30 minutes at 4C by using
appropriate antibody or isotype control as described pre-
viously.30 Monocytes were identiﬁed on the basis of CD14
expression, and the expression of other cell surface markers
was analyzed on CD14þ cells. For intracellular detection of
a-SMA, LX2 cells were ﬁxed with 1% paraformaldehyde,
permeabilized with 1% Tween 20, and stained with a-SMA
antibody.31 Data acquisition was performed on a BD-LSR II
(BD Biosciences, San Diego, CA), and the data were analyzed
with FlowJo software (Tree Star, Ashland, OR). We deter-
mined the mean ﬂuorescence intensity (MFI) for the gated
positive population for each of the respective monocyte/
macrophage markers.
Amnis Flowsight (EMD Millipore, Billerica, MA), which
combines ﬂow cytometry with real-time confocal imaging,
was used for studying the expression of collagen in mono-
cytes. Brieﬂy, CD14 monocytes were isolated from both
healthy controls and HCV-infected patients’ peripheral blood.
Approximately 105 cells were suspended in buffer containing
Fc receptor-blocking agent (Miltenyi Biotec, Inc). Cells then
were stained with 40,6-diamidino-2-phenylindole, anti-CD45
PE, anti-CD206 APC, and anti-CD14 PE-Cy7, and thenwashed,
ﬁxed, and permeabilized with the CytoFix/cytoperm kit
(BD Pharmingen). Cells then were incubated with rat-anti-
human pro-Col-Ia or isotype control, washed, and ﬁnally
stained with FITC-conjugated secondary antibody. The sam-
ples were acquired on the Amnis Flowsight, and analysis of
the datawas performedwith IDEAS software (EMDMillipore,
Seattle, WA).
Western Blot Analysis
Western Blot analysis was performed for CD68, CD206,
and b-actin as previously described.32Statistical Analysis
All values are expressed as means ± SEM obtained from
3 or more independent experiments. The Student t test and
1-way or 2-way analysis of variance test was used to
compare means of multiple groups. A P value less than .05
was considered statistically signiﬁcant. GraphPad
Prism software (La Jolla, CA) was used for statistical
analysis.
Results
HCV-Infected Hepatoma Cells Induce
Differentiation of Monocytes Into
Polarized Macrophages
Monocytes play important roles in inﬂammatory and
innate immune responses during HCV infection.33,34 Mono-
cytes from HCV-infected patients express TNFa on exposure
to HCV proteins and show hyper-responsiveness to Toll-like
receptor 2 and 4 ligands.15,35 Monocytes are highly plastic
and home to tissues where they differentiate to macro-
phages in response to the local environment. To test the
hypothesis that HCV infection can lead to monocyte differ-
entiation into macrophages, we performed in vitro
co-cultures of HCV-naive healthy monocytes with HCV-
infected Huh7.5/JFH-1 cells. We observed that exposure to
Huh7.5/JFH-1 cells for 7 days induced monocyte differen-
tiation into MFs characterized by increased CD14, CD68,
and CD11c expression compared with cells co-cultured with
control Huh7.5 cells (Figure 1A and Supplementary
Figure 2). The MFI of CD14, CD68, and CD11c also was
increased in HCV MF compared with controls, indicating the
MF phenotype (Figure 1B).
Next, we sought to identify the phenotype of the HCV
MF. MFs generated from monocytes in the presence
of granulocyte-macrophage colony–stimulating factor or a
combination of interferon-g plus lipopolysaccharide were
positive controls for M1 MFs (classically activated) that had
signiﬁcantly increased expression of CD16, CD40, and CD86
(Supplementary Figure 3A and B). Macrophage colony–
stimulating factor– or IL4-induced M2 MFs (alternatively
activated) had high CD206, CD163, and DC-SIGN expres-
sions36,37 (Supplementary Figure 3A and C). However, we
also observed CD40 and DC-SIGN expression in both M1-
and M2-positive controls, indicating that some of the
markers are expressed under both polarizing conditions.
HCV MF showed increased expression of M2 markers
(CD206, CD163, and DC-SIGN) and no signiﬁcant change in
the expression of M1 markers (CD16, CD40, and CD86)
compared with monocytes co-cultured with Huh7.5 cells
(Figure 1C–F). These results suggest that HCV-infected
hepatoma cells promote monocyte differentiation into MF
with predominant M2 MF marker expression.Monocytes Co-cultured With HCV-Infected
Hepatoma Cells Results in Production of
Both M1 and M2 Polarizing Cytokines
Next, we evaluated the cytokine secretion pattern of
monocytes co-cultured with HCV-infected hepatoma cells.
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Figure 2. HCV-induced M2-like macrophages secrete proinﬂammatory and anti-inﬂammatory cytokines. Monocytes
obtained from healthy donors were co-cultured with or without Huh7.5 or Huh7.5/JFH-1 cells for 7 days. Cell culture
supernatant was collected on days 3 and 7 of the experiment and enzyme-linked immunosorbent assay was performed for
(A) TNFa, (B) IL1b, (C) IL10, and (D) TGF-b. Results are expressed as means ± SEM (n ¼ 4–7; *P  .05, ***P  .001, and
****P  .0001). All P values were determined by 2-way analysis of variance.
306 Saha et al Cellular and Molecular Gastroenterology and Hepatology Vol. 2, No. 3We observed that monocytes co-cultured with Huh7.5/JFH-1
cells secreted TNFa and IL1b by day 3, which was sustained
even on day 7 (Figure 2A and B). However, monocyte
secretion of the M2-polarizing cytokines, IL10 and TGF-b,
also signiﬁcantly increased in the presence of Huh7.5/JFH-1
cells over time, peaking on day 7 (Figure 2C and D). Huh7.5
cells alone secreted negligible levels of these cytokines
regardless of HCV infection (Supplementary Figure 4). These
results showed that monocytes co-cultured in the presence
of Huh7.5/JFH-1 cells secreted both proinﬂammatory and
anti-inﬂammatory cytokines (Figure 2).Figure 1. (See previous page). Long-term co-culture of heal
leads to monocyte differentiation into macrophages charac
cells or Huh7.5/JFH-1 cells were co-cultured with monocytes
harvested and the phenotypic characteristics of monocytes afte
dot plots show the expression of (A) MFmarkers (CD14, CD68, a
(E) M2 MF markers (CD206, CD163, and DC-SIGN). The dat
expression levels of the MF markers in terms of MFI are shown
the levels of (B) CD14, CD68, and CD11c, (D) M1 markers CD1
DC-SIGN. Results are expressed as means ± SEM (N ¼ 8–10).
control. #P  .05 compared with Huh7.5 co-culture. All P valueDespite the increased expression of M1-polarizing
cytokines, TNFa and IL1b, we observed an increase in the
M2 MF markers on the HCV MF (Figure 1). This led us to
assess whether proinﬂammatory cytokines induced in the
early phase of monocyte-Huh7.5/JFH-1 co-culture could
contribute to the anti-inﬂammatory response characterized
by TGF-b production. IL1b regulates TGF-b signaling in
human kidney epithelial cells where prolonged IL1 stimu-
lation (or chronic inﬂammation) leads to enhanced TGF-b
signaling.38 We found that addition of various doses of
IL1–receptor antagonist (IL1RA), anakinra, to co-cultures ofthy human monocytes with HCV-infected hepatoma cells
terized with increased expression of M2 markers. Huh7.5
obtained from healthy donors for 7 days. The cells were
r 7 days of co-culture were evaluated by ﬂow cytometry. The
nd CD11c), (C) M1 MFmarkers (CD16, CD40, and CD86), and
a are representative of 8–10 independent experiments. The
for different co-culture conditions. The bar graphs represent
6, CD40, and CD86, and (F) M2 markers CD206, CD163, and
(B, D, and F) *P  .05 and **P  .01 compared with medium
s were determined by 1-way analysis of variance.
Figure 3. IL1-receptor antagonist, anakinra, inhibits TGF-b secretion in monocytes co-cultured with HCV-infected
hepatoma cells. Monocytes were co-cultured with Huh7.5 or Huh7.5/JFH-1 cells in the presence of anakinra (1–100 mg/mL)
for 7 days. Culture supernatants were collected and assayed for (A) IL1b, (B) TGF-b, and (C) IL10. Flow cytometry analysis of
the M2 markers (D) CD206, (E) CD163, and (F) DC-SIGN also were performed on the monocytes from the co-cultures. Results
are represented as means ± SEM from 3–7 independent experiments. *P  .05, **P  .01, ***P  .001, and ****P  .0001. All P
values were determined by 2-way analysis of variance.
May 2016 HCV Infection and Monocyte Plasticity 307monocytes with HCV-infected hepatoma cells attenuated
the HCV-induced M2-like MF phenotype (Figure 3).
Secretion of IL1b was reduced in a dose-dependent manner
in monocytes cultured with Huh7.5/JFH-1 cells in the
presence of IL1RA (Figure 3A). That was expected given
the autoregulatory feedback loop of IL1 production.39
Importantly, IL1RA treatment inhibited secretion of TGF-b,
but not IL10, in the monocyte-Huh7.5/JFH-1 co-cultures
(Figure 3B and C). Furthermore, when we evaluated the
expression of M2 MF markers on IL1RA-treated co-cultures
of monocytes with Huh7.5/JFH-1, we observed an attenua-
tion of CD206, CD163, and DC-SIGN expression
(Figure 3D–F). The levels of DC-SIGN were decreased to a
greater extent compared with CD206 and CD163expression, which suggests that inhibiting IL1 does not
completely abolish M2–MF polarization. Thus, these results
showed that the induction of IL1b in the presence of HCV-
infected hepatoma cells promoted monocyte differentia-
tion into TGF-b producing MF.TGF-b Released by HCV MF Leads
to Hepatic Stellate Cell Activation
To assess the functional role of these HCV MFs, we
asked whether they could induce HSC activation. LX2, a
human HSC line, was treated with the supernatants
collected from the 7-day monocyte-Huh7.5/JFH-1 co-culture
experiments. We studied the expression of collagen (COL)
Figure 4. TGF-b secreted
from HCV-educated mono-
cytes mediates proﬁbrogenic
effects on HSCs. LX2 cells
were cultured for 6 days in
the presence of supernatant
obtained from a 7-day mono-
cyte (Mo)-Huh7.5 or Huh7.5/
JFH-1 co-culture experiment.
LX2 cells also were treated with
supernatant from Huh7.5 or
Huh7.5/JFH-1 cells. LX2 cells
also were treated with or
without TGF-b (2.5 ng/mL). To-
tal RNA was isolated, comple-
mentary DNA was transcribed,
and real-time polymerase chain
reaction was performed. Rela-
tive mRNA expression of (A)
COL-1A, (B) TIMP1, and (C)
a-SMA was determined. The
data are represented as means
± SEM, N¼ 5–7, where *P  .05
and **P  .01 (unpaired t test).
(D) LX2 cells were cultured for 6
days as described earlier and
intracellular a-SMA levels were
determined by ﬂow cytometry.
The representative histogram
depicts the expression of
a-SMA in LX2 cells treated with
Mo-Huh7.5/JFH-1 co-culture
supernatants and TGF-
b–treated LX2 cells. LX2 cells
were cultured in the presence of
control IgG1 or neutralizing
anti–TGF-b antibody under
similar conditions as described
earlier for 6 days and the rela-
tive mRNA expression of (E)
COL-1A, (F) TIMP1, and (G)
a-SMA was measured. (H)
a-SMA protein levels also were
determined by ﬂow cytometry
and a representative histogram
is shown for the LX2 cells
treated with Mo-Huh7.5/JFH-1
supernatants in the presence
of anti–TGF-b neutralizing anti-
bodies and control IgG1. (E–G)
The data are representative of
means ± SEM, N ¼ 4, where
*P  .05, **P  .01, and
****P  .0001 (2-way analysis of
variance). (D and H) Data are
representative of 2 independent
experiments.
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a-SMA messenger RNA (mRNA) and observed signiﬁcant
increases at day 6 (Figure 4A–C). TGF-b, as a positive con-
trol, increased mRNA levels of COL1A, TIMP1, and a-SMA in
LX2 cells. Supernatants of Huh7.5/JFH-1 cells (without
monocytes) resulted in a minimal increase in COL1A, TIMP1,
and a-SMA mRNA expression in LX2 cells, suggesting that
HCV-infected hepatoma cells do not directly activate LX2
cells. We also measured the levels of a-SMA protein in HSCs
treated with supernatants from the monocyte Huh7.5/JFH-1
and observed increased a-SMA, which was comparable with
TGF-b–treated LX2 cells (Figure 4D).
Because TGF-b levels were increased in the 7-day
co-cultures of monocyte Huh7.5/JFH-1, we studied the
effect of TGF-b neutralization on LX2 activation. We observed
that the proﬁbrotic effect of the supernatants derived from
the monocyte-Huh7.5/JFH-1 co-cultures was prevented by
TGF-b neutralization (Figure 4E–G). LX2 cells pretreated with
anti–TGF-b–neutralizing antibodies and cultured in the
presence of monocyte-Huh7.5/JFH-1 co-culture supernatant
had decreased a-SMA protein levels compared with
control IgG1-treated LX2 cells (Figure 4H). These results
showed that TGF-b released from HCV MFs leads to HSC
activation.Monocyte to Macrophage Differentiation Is
Induced by Cell-Free HCV and Does
Not Require Cell–Cell Contact
Next, we performed experiments to evaluate whether
cell-free HCV can have similar effects on monocyte activa-
tion as observed in the presence of HCV-infected hepatoma
cells. Because JFH-1–infected Huh7.5 cells release HCV into
the culture supernatant we tested effects of cell-free HCV on
monocytes.40 Similar to HCV-infected hepatoma cells, the
addition of isolated HCV directly to monocytes increased
CD14, CD68, CD206, and CD163 expression and changed
monocyte morphology over a 7-day period (Figure 5A–D
and Supplementary Figure 5A and B). TNFa and IL1b pro-
duction increased in monocytes cultured with HCV, and a
time-dependent increase in IL10 and TGF-b levels suggested
that cell-free HCV can induce the monocyte to MF differ-
entiation (Figure 5E–H). Collectively, these results showed
that without cell–cell contact, cell-free HCV robustly and
directly inﬂuenced monocyte differentiation into MFs that
expressed M2 surface markers and a mixed M1/M2 cyto-
kine secretion pattern.M2 MF Markers Are Expressed on Circulating
Monocytes in the Blood and in the Liver in
Chronic HCV-Infected Patients
Our in vitro results showed the role of HCV in medi-
ating monocyte differentiation to MFs. During chronic HCV
infection, monocytes continuously are exposed to HCV and
viral RNA/protein in circulation.35 Thus, we wanted to
evaluate the phenotype of chronic HCV patients’ monocytes
based on expression of M1 (CD40, CD86) and M2 (CD206,
CD163) markers. We found a signiﬁcantly increasedpercentage of M2 marker CD206 expression in HCV-
infected patients compared with controls (Figure 6A).
Expression of M1 marker CD40 and M2 marker CD163
were not increased signiﬁcantly as compared with controls
(Figure 6A). There was no change in the percentage of
CD14þCD86þ cells in the patient vs control group
(Figure 6A). The MFI of CD40, CD206, and CD163
increased, but that of CD86 decreased in the HCV-infected
group as compared with controls (Supplementary
Figure 6). Next, we performed a correlation analysis be-
tween the percentage of CD14þCD206þ circulating mono-
cytes with the extent of liver ﬁbrosis (Metavir score) in
patients with HCV infection. As shown in Figure 6B,
Spearman analysis showed a positive correlation of
CD14þCD206þ circulating monocyte percentage with the
ﬁbrosis score (r ¼ 0.839; P < .0001).
Next, we evaluated the expression of MF markers in the
livers of HCV-infected patients. Previous studies have shown
increased number and activation of MFs in the liver in
chronic HCV infection.15,35 We found increased levels of M2
MF markers; CD206, IL10, and TGF-b mRNA in the HCV-
infected liver were observed as compared with controls
(Figure 6C). We also observed that the MF marker, CD68,
was up-regulated along with increased mRNA expression of
M1 MF markers, TNFa and IL1b, compared with control
livers (Figure 6D). There was a signiﬁcant increase in the
protein expression of MF markers, CD68 and CD206, in the
liver of HCV-infected patients as compared with controls
(Figure 6E and F). Together, these results showed that the
frequency and expression of M2 MF markers was increased
in circulating monocytes and the expression of these markers
also was increased in the liver of HCV-infected patients.HCV Infection Leads to Generation
of Collagen-Expressing Monocytes
In Vivo and In Vitro
The presence of monocytes expressing M2-MF markers
prompted us to further investigate the characteristics of
these circulating monocytes. Previous studies indicated that
CD14þ peripheral blood monocytes can differentiate into
cells that express collagen, which are attracted to the sites of
tissue injury and mediate tissue repair and ﬁbrosis.41,42
Here, we found increased mRNA levels of collagen
(COL1A) in the monocytes co-cultured with Huh7.5/JFH-1
cells (Figure 7A). To determine the in vivo relevance of
this ﬁnding, we next tested collagen expression in the
PBMCs of HCV-infected patients. There was a signiﬁcant
increase in the mRNA levels of COL1A in PBMCs in HCV-
infected patients as compared with healthy controls
(Figure 7B).
We found a signiﬁcantly increased number of CD14þ
monocytes expressing procollagen 1a in HCV-infected
patients compared with controls (Figure 7C). Procollagen
1a is packaged in the Golgi bodies and undergoes
post-translational modiﬁcation before it is secreted from a
cell.43 Because monocytes from the HCV-infected patients
also showed an M2 phenotype we studied the
co-expression of pro-Col1a and CD206 in CD14þ
Figure 5. Cell-free HCV induces monocyte differentiation. Monocytes were cultured in the presence of macrophage
colony–stimulating factor (M-CSF), Huh7.5 culture supernatant concentrate, or HCV concentrate for 7 days and immuno-
stained for (A) CD14, (B) CD68, (C) CD206, and (D) CD163. (E) TNFa, (F) IL1b, (G) IL10, and (H) TGF-b levels were measured on
days 3, 5, and 7 by enzyme-linked immunosorbent assay from culture supernatant. The data are represented as means
± SEM, N ¼ 4–6, *P  .05, **P  .01, ***P  .001.
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Figure 6. M2 macrophage markers are up-regulated on circulating monocytes and liver during chronic HCV infection.
(A) CD14þ monocytes from controls and HCV-infected patients were immunophenotyped by ﬂow cytometry and the per-
centage of cells expressing CD40, CD86, CD206, and CD163 markers are shown. The data are represented as means ± SEM
(controls, N ¼ 7; HCV, N ¼ 11). (B) Correlation analysis of the percentage of CD14þCD206þ circulating monocytes and the
ﬁbrosis stage is shown (HCV, N ¼ 26). The statistical analysis was performed using Spearman correlation. (C) mRNA
expression of CD206, IL10, and TGF-b, and (D) CD68, TNFa, and IL1b were determined in liver biopsy specimens from
controls or HCV-infected patients by real-time polymerase chain reaction. The data are represented as means ± SEM
(controls, N ¼ 10–11; HCV, N ¼ 12). The P value was determined by unpaired t test. (E and F) Protein level expression of CD68
and CD206 in the liver of control and HCV-infected patients is shown. Western blot showing the expression of CD68 with
digital imaging at higher exposure for liver samples (controls, N ¼ 3; HCV, N ¼ 3). b-actin was used as the loading control. The
bar graph shows the fold-change in CD68 or CD206 levels as compared with b-actin (controls, N ¼ 6; HCV, N ¼ 6). The P value
was determined by an unpaired t test. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
May 2016 HCV Infection and Monocyte Plasticity 311monocytes. We observed that 10%–15% of monocytes that
expressed collagen also expressed CD206 in monocytes
from HCV-infected patients, which was approximately 0.4%
of the total circulating cells, although there was no collagen
expression in monocytes from controls (Figure 7D and E).
Finally, to visualize the presence of collagen in monocytes
from HCV-infected patients we used Amnis image streamtechnology (Amnis Flowsight). We observed that circulating
monocytes from HCV-infected patients expressed pro-
Col1a but not from healthy controls (Figure 7G and H). We
also found observed co-localization of pro-Col1a and
CD206 on CD14þ monocytes from HCV-infected patients
(Figure 7I). These results showed that during HCV infec-
tion, collagen-producing CD14þ monocytes are present
312 Saha et al Cellular and Molecular Gastroenterology and Hepatology Vol. 2, No. 3in the circulation in vivo and may contribute to liver
ﬁbrogenesis.Discussion
Innate immune responses play a critical role in the
control and resolution of acute HCV infection and contribute
to chronic inﬂammation and liver ﬁbrosis.5,44 The mecha-
nisms by which HCV-infected hepatocytes affect circulating
monocytes and liver MFs and the effects of HCV onmonocyte differentiation are only partially understood.
Because of the lack of animal models of HCV infection, most
of the studies are performed in vitro using the well-
established HCV infection culture system.29,40 By using
co-cultures of human monocytes and HCV-infected hepa-
toma cells or cell-free HCV we showed that HCV induced
differentiation of monocytes to MF with mixed M1/M2
cytokine production and M2-polarized surface marker
expression. Our data indicated that M2-MF–derived TGF-b
acted as a mediator of HSC activation and ﬁbrosis. We also
May 2016 HCV Infection and Monocyte Plasticity 313found increased frequency of circulating monocytes
expressing M2 marker in the blood of chronic HCV-infected
patients and identiﬁed CD14þCD206þcollagenþ monocytes
in the circulation that correlated positively with liver
ﬁbrosis in HCV-infected patients.
Peripheral blood monocytes constantly enter the liver
where they interact with HCV-infected hepatocytes, cell-free
virus, and replenish liver MFs.35 Experimental animal
models of liver diseases have shown that the disease path-
ogenesis is mediated partially by Kupffer cells, but largely is
dependent on the recruitment of monocytes into the injured
and inﬂamed liver.45 Thus, in this study we performed
co-culture experiments to understand the effect of HCV-
infected hepatoma cells on the phenotype and function of
monocytes. Consistent with previous studies that showed
activation of Kupffer cells, monocytes, and MFs in chronic
HCV infection, we found increased activation and produc-
tion of cytokines by monocytes exposed to HCV.15,46 Our
studies showed that HCV-infected hepatoma cells triggered
monocytes to differentiate into a MF phenotype (CD14high,
CD68high, CD11chigh) with increased M2-marker (CD206þ,
CD163þ, DC-SIGNþ) expression.
In patients with viral hepatitis, increased numbers of
Kupffer cells (CD14þCD68þ) are found around the region of
damage and ﬁbrosis that has been associated with liver
injury.45 A detailed study from liver tissues obtained from
nonviral hepatitis patients showed that a speciﬁc monocyte
population accumulated within the liver, which had high
phagocytic activity and released both inﬂammatory and
proﬁbrogenic cytokines.14 Thus, it is likely that the chronic
presence of virus in the circulation and in the liver during
HCV infection may trigger accumulation of recruited
monocytes and alter the phenotype of the resident MFs in
the liver. Persistent inﬂammation generally is accompanied
by negative feedback mechanisms, and during chronic viral
infections M2 MFs showing potent anti-inﬂammatory,
wound healing, and ﬁbrotic capacity may accumulate in
the liver.45,47 Although M2 MF are essential to restore ho-
meostasis in acute inﬂammation, they also produce growth
factors and cytokines, including TGF-b1 and platelet-derived
growth factors, which stimulate ﬁbroblasts.48 Our results
support a model in which chronic HCV presence leads to
activation of proﬁbrotic MFs. We found that HCV-infectedFigure 7. (See previous page). Collagen-expressing monoc
patients. (A) Isolated monocytes from healthy donors were
mRNA levels of COL-1A were measured by real-time polymeras
n ¼ 3 experiments. (B) PBMCs were isolated from healthy donor
of COL-1A were measured. (C–G) Isolated monocytes from hea
immunostained with antibodies against CD14, CD45, and CD20
antibody. Expression of these markers was studied by ﬂow
Pro-Col1aþ in controls and HCV-infected patients was determi
cells in controls and HCV-infected patients was measured. (E) F
value was determined by unpaired t test. (F–I) Confocal images
CD45 (pink), CD206 (red), and 40,6-diamidino-2-phenylindol
magniﬁcation, 20) for 3 representative healthy donors and 4
plots for the circulating monocytes expressing CD206 and proC
(H) Co-localization of CD14 (yellow) and pro-Col1a (green) (orig
and HCV-infected patients (N ¼ 2). (I) Co-localization of C
magniﬁcation, 20) for 2 representative healthy donors and HChepatoma cells triggered early induction of proin-
ﬂammatory cytokines (TNFa and IL1b) whereas TGF-b and
IL10 were predominant in the late cytokine response.
Although production of anti-inﬂammatory cytokines (IL10,
TGF-b) is a component of the natural evolution of late-phase
inﬂammation, the results from our experiments using
IL1RA, anakinra, indicate that the early induction of IL1b
contributes to increased TGF-b production in HCV-induced
MF. Further, anakinra inhibited production of TGF-b and
not IL10, which in turn led to decreased expression of M2
markers on the monocytes co-cultured with Huh7.5/JFH-1.
This suggested the direct role of TGF-b in inducing mono-
cyte differentiation and/or macrophage polarization during
HCV infection. This indicates an autoregulatory loop by
which HCV skews innate immune response to its advantage.
IL1b is a proﬁbrotic mediator in liver and lung ﬁbrosis
whereas TGF-b signaling plays a pivotal role in cellular
responses by promoting cell proliferation, differentiation,
and apoptosis.23,25,43 HCV-infected patients express high
levels of TGF-b in serum and liver, which correlates with the
degree of ﬁbrosis.23 Expression of HSC activation markers,
COL1A, TIMP-1, and a-SMA, in LX2 cells was decreased with
TGF-b inhibition in monocyte and Huh7.5/JFH-1 co-culture
supernatants. Further experiments with primary HSCs could
validate our ﬁnding with LX2 cells on the effects of mono-
cyte polarization during HCV infection on HSC activation.
The effects of the HCV-infected hepatoma cells as well as
cell-free virus on the monocyte phenotype and function
were observed in an in vitro culture system, however, this
may not entirely mimic the complex environment of the
liver where the phenotype of the monocyte/MFs are inﬂu-
enced by the presence of other immune and nonimmune
cells. The limitation of our study was that it characterized
functions of circulating monocytes that should be inter-
preted carefully regarding the function of monocytes in the
HCV-infected liver. Nonetheless, our in vivo results under-
score the importance of the in vitro ﬁndings because we
show that during HCV infection there is a signiﬁcant
increase in the expression of CD14þ monocytes expressing
the M2 marker CD206. This increase in the M2 marker
expressing monocytes correlated positively with
liver ﬁbrosis in the HCV-infected patients. The mRNA and
protein expression suggested the presence of M2 MFs inytes showing M2 phenotype identiﬁed in HCV-infected
co-cultured with Huh7.5 or Huh7.5/JFH-1 cells for 8 days.
e chain reaction. The data are represented as means ± SEM,
s (N ¼ 2) and HCV-infected patients (N ¼ 6), and mRNA levels
lthy donors (N ¼ 5) and HCV-infected patients (N ¼ 10) were
6. Cells were ﬁxed and permeabilized to stain with pro-col-1a
cytometry and Amnis Flowsight. (C) Frequency of CD14þ
ned. (D) Frequency of CD206-expressing CD14þ Pro-Col1aþ
requency of CD206þCD14þ Pro-Col1aþ cells in circulation. P
of monocytes expressing CD14 (yellow), pro-Col1a (green),
e (DAPI) (purple) staining for nucleus is shown (original
representative HCV-infected patients. (G) Representative dot
ol1-a is shown for a healthy control and HCV-infected patient.
inal magniﬁcation, 20) is shown for healthy controls (N ¼ 2)
D14 (yellow), CD206 (red), and pro-Col1a (green) (original
V-infected subjects (N ¼ 2) have been shown.
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derscore the role of HCV in inﬂuencing monocyte differen-
tiation and polarization.
CD14þ monocytes are precursors not only for MFs, but
also for ﬁbrocytes.41 Fibrocytes have features of both MFs
and ﬁbroblasts and express markers of both hematopoietic
cells (CD34, CD43, CD45, Lymphocyte-speciﬁc protein 1,
major histocompatibility complex class II) and stromal cells
(collagen I and III).41,42,49 In addition, a population of
CD45þ/CD14þ/Col-Iþ monocytes also has been described in
the circulation of patients with systemic sclerosis.50 Although
monocytes give rise to ﬁbrocytes, the expression of CD14 on
ﬁbrocytes is controversial and thus, the term ﬁbrocytes is
used for the cells that are CD14-, whereas CD14þ cells are
referred to as collagen-producing monocytes.50,51 Increased
numbers of ﬁbrocytes are reported in diseases characterized
by chronic inﬂammation; animal models also have implicated
ﬁbrocytes in the development of tissue ﬁbrosis involving
lungs, liver, heart, and kidney.42,52,53 Collagen-producing
monocytes are detected in the circulation and the lungs of
systemic sclerosis–interstitial lung disease patients and are
important in the progression of lung ﬁbrosis.51 Nunnari
et al54 showed the correlation of circulating ﬁbrocytes
CD45þ/CD34þ/Col-Iþ with liver ﬁbrosis in chronic HCV
patients. We detected collagen-producing monocytes in the
blood of chronic HCV patients, but not in healthy subjects. We
also showed that a signiﬁcant percentage of collagen-
producing monocytes from HCV-infected patients also
expressed the M2 marker CD206. This suggested that, ﬁrst,
during HCV infection, some monocytes acquire a proﬁbrotic
characteristic and the frequency of proﬁbrotic monocytes is
increased in the circulation compared with normal controls.
Second, in HCV-infected patients, the collagen-producing
CD14þ monocytes comprised a fraction of the circulating
M2 monocyte population of chronic HCV-infected patients,
which could function as a biomarker. Our results also sug-
gested that the presence of M2 markers in the liver and blood
during chronic HCV infection positively correlated with liver
ﬁbrosis in HCV-infected patients. In the present study, we
analyzed a small number of HCV-infected patients, thus it is
important to screen for these markers in a larger cohort of
patients at different stages of liver ﬁbrosis to establish
CD14þCD206þ cells as potential biomarkers of ﬁbrosis.
In summary, our data show a new aspect of HCV and
host interactions in which HCV-infected hepatocytes pro-
mote monocyte differentiation into MFs with a mixed M1/
M2 cytokine proﬁle and M2 surface phenotype. We found
that HCV-mediated monocyte differentiation leads to a MF
phenotype that is proﬁbrotic, with characteristics of M2
(alternatively activated) MFs, leading to HSC activation.
Furthermore, our results suggest that the circulating
monocyte phenotype from HCV patients can act as a marker
for liver ﬁbrosis in chronic hepatitis C infection.References
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Supplementary Figure 1. Puriﬁcation of CD14D monocytes from human PBMCs. Monocytes were isolated from human
PBMCs using CD14 microbeads, an MS Column, and a MiniMACS separator. (A) PBMCs and (B) monocytes after isolation
were stained with CD14-APC antibody. Representative dot plots and histograms are shown.
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Supplementary Figure 2. Monocytes differentiate into
macrophages in the presence of Huh7.5/JFH-1 cells.
Monocytes were isolated from healthy donors and were
co-cultured with Huh7.5 cells with or without JFH-1 infection.
After 7 days of culture, photographs of the cells were taken
with a Nikon DS-QiMc (Nikon Instruments Inc, Melville, NY)
camera attached to a Nikon Eclipse TS100 microscope at
40 magniﬁcation. The experiments were repeated 8–10
times and representative images of the co-culture conditions
have been shown.
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Supplementary Figure 3. Expression of M1 and M2 markers on monocytes differentiated in the presence of various M1
and M2 polarizing agents. Monocytes were cultured in the presence of macrophage colony–stimulating factor (M-CSF)
(50 ng/mL) or granulocyte-macrophage colony–stimulating factor (GM-CSF) (50 ng/mL) for 7 days or were cultured in the
presence of M-CSF for 6 days and then treated with interferon (IFN)g (20 ng/mL) þ lipopolysaccharide (LPS) (100 ng/mL) or IL4
(20 ng/mL) for 18 hours to generate M1 and M2 MFs, respectively. The cells were harvested and the phenotypic charac-
teristics were evaluated by ﬂow cytometry. (A–C) The expression levels of the MF markers in terms of MFI are shown for
different co-culture conditions. The bar graphs represent the levels of (A) CD14, CD68, and CD11c, (B) M1 markers (CD16,
CD40, and CD86), and (C) M2 markers (CD206, CD163, and DC-SIGN). Results are expressed as means ± SEM, n ¼ 8–10.
(A–C) *P  .05, **P  .01, and ***P  .001 compared with medium control. All P values were determined by 1-way analysis of
variance.
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Supplementary Figure 4. Cytokine secretion by HCV-
infected Huh7.5 cells was comparable with uninfected
Huh7.5 cells. Huh7.5 cells were either infected with JFH-1 or
left uninfected. Culture supernatant was collected after 7
days and TNFa, IL1b, IL10, and TGF-b levels were deter-
mined by enzyme-linked immunosorbent assay. The data are
represented as means ± SEM, n ¼ 4. The P values were
determined by an unpaired t test.
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Supplementary Figure 5. HCV inducesmonocyte
differentiation into macrophages. Monocytes
were isolated fromhealthydonors and cultured alone
or with Huh or HCV concentrate for 7 days. (A)
Photographs of the cellswere takenwith aNikonDS-
QiMc camera attached to a Nikon Eclipse TS100
microscope at a magniﬁcation of 20. A represen-
tative image is shown. (B) Representative histogram
plots of CD14, CD68, CD206, and CD163 on
monocytes alone and cells treated with Huh
concentrate or viral concentrate.
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Supplementary Figure 6. M2-macrophage markers are up-regulated on circulating monocytes. CD14þ monocytes from
healthy controls and HCV-infected patients were immunophenotyped by ﬂow cytometry for CD40, CD86, CD206, and CD163.
The representative histogram plots and the MFI are shown.
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Supplementary Table 1.Clinical Characteristics of the
HCV-Infected Patients
Serial number Genotype
Viral load,
log IU/mL Fibrosis stage
1 1a 5.13 Grade 4/4
2 NA 4.01 Grade 4/4
3 NA 6.95 Grade 1/4
4 NA 5.71 Grade 4/4
5 3 6.86 Grade 4/4
6 NA 2.84 Grade 4/4
7 NA NA Grade 3/4
8 NA 5.50 Grade 4/4
9 NA NA Grade 4/4
10 NA 5.46 Grade 4/4
11 NA 3.11 Grade 4/4
12 NA 5.68 NA
NOTE. The HCV genotype, viral load, and the ﬁbrosis stage
are shown for the HCV-infected patients who had a liver bi-
opsy. Metavir scoring was used for ﬁbrosis scoring. The
ﬁbrosis was graded on a 5-point scale from 0 to 4. Fibrosis
scores were as follows: F0, no ﬁbrosis; F1, portal ﬁbrosis
without septa; F2, portal ﬁbrosis with few septa; F3,
numerous septa without cirrhosis; and F4, cirrhosis. NA, not
available.
Supplementary Table 2.Clinical Characteristics of the
HCV-Infected Patients
Serial number Genotype
Viral load,
log IU/mL
Fibrosis
stage
1 2b 6.40 Grade 0/4
2 1a 6.61 Grade 2/4
3 1a 5.71 Grade 1/4
4 1b 5.72 Grade 2/4
5 1a 4.69 Grade 0/4
6 1b 5.79 Grade 1/4
7 3a 6.12 Grade 3/4
8 1a 6.71 Grade 0/4
9 1a 5.06 Grade 0/4
10 1a 6.07 Grade 2/4
11 1a 5.73 Grade 1/4
12 1a 6.51 Grade 2/4
13 2b 6.55 Grade 2/4
14 1a 7.92 Grade 4/4
15 1a 6.5 Grade 1/4
16 3a 6.12 Grade 2/4
17 1a 5.71 Grade 1/4
18 3a 5.93 Grade 3/4
19 1a 6.61 Grade 2/4
20 1b 4.6 Grade 3/4
21 1a 1.2 Grade 2/4
22 1b 6.03 Grade 3/4
23 2b 6.6 Grade 0/4
24 3a 5.93 Grade 24
25 NA 2.56 Grade 0/4
26 1a 7 Grade 1/4
NOTE. The HCV genotype, viral load, and the ﬁbrosis stage
are shown for the HCV-infected patients who provided blood
samples for the study. Metavir scoring was used for ﬁbrosis
scoring. The ﬁbrosis was graded on a 5-point scale from 0 to
4. Fibrosis scores were as follows: F0, no ﬁbrosis; F1, portal
ﬁbrosis without septa; F2, portal ﬁbrosis with few septa; F3,
numerous septa without cirrhosis; and F4, cirrhosis. NA, not
available.
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Supplementary Table 3.Primer Sequences Used for Real-Time Polymerase Chain Reaction Analysis
Gene symbol Forward primer (5’-3’) Reverse primer (5’-3’)
GAPDH GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC
18s GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG
CD68 GAACCCCAACAAAACCAA GATGAGAGGCAGCAAGAT
IL1b ATGATGGCTTATTACAGTGGCAA GTCGGAGATTCGTAGCTGGA
TNFa ATCTTCTCGAACCCCGAGTGA CGGTTCAGCCACTGGAGCT
IL10 ATGCCCCAAGCTGAGAACCAAGACCCA TCTCAAGGGGCTGGGTCAGCTATCCCA
TGF-b CACCGGAGTTGTGCGGCAGT GGCCGGTAGTGAACCCGTTGAT
CD206 ACAAAAGCTGACACAAGGAAGATG TCAGGAGGATCACAATGATGACTAC
COL-1A GGCGGCCAGGGCTCCGAC AATTCCTGGTCTGGGGCACC
TIMP1 CACCCACAGACGGCCTTCT TCTGGTGTCCCCACGAACTT
a-SMA CTGTTCCAGCCATCCTTCAT CGGCTTCATCGTATTCCTGT
NOTE. The forward and reverse primer sequences used for real-time polymerase chain reaction assay in the study are shown.
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